HDAC9 and sarcoma: Previously, in sarcoma cells treated with the multi-kinase inhibitor pazopanib and the HDAC inhibitors sodium valproate or entinostat we also observed, in drug-resistant cells, that c-MET as well as ERBB1 had become activated (10).